logo
logo
Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc.

NASDAQ•ETON
CEO: Mr. Sean E. Brynjelsen
セクター: Healthcare
業種: Biotechnology
上場日: 2018-11-13
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
連絡先情報
21925 W. Field Parkway, Suite 235, Deer Park, IL, 60010-7278, United States
847-787-7361
www.etonpharma.com
時価総額
$457.78M
PER (TTM)
-68.7
34.3
配当利回り
--
52週高値
$23.00
52週安値
$11.09
52週レンジ
50%
順位56Top 81.7%
2.5
F-Score
改良版 Piotroski 分析
8年ファンダメンタル
弱い • 2.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2018-2025

財務ダッシュボード

Q3 2025 データ

売上高

$22.46M+117.54%
直近4四半期の推移

EPS

-$0.07-389.26%
直近4四半期の推移

フリーCF

$11.74M+297.76%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine Month Revenue Surge Nine months total revenues hit $58.67M, marking a substantial 114.4% increase versus prior year period driven by product sales.
Gross Profit Expansion Nine months gross profit reached $29.64M, increasing 75.0% due to strong product sales and royalties growth.
Strong Operating Cash Flow Operating cash flow provided $22.08M cash over nine months, a major improvement from $1.73M provided previously.
Cash Position Solidified Cash and equivalents totaled $37.12M at period end, supporting short-term liquidity needs for the next twelve months.

リスク要因

Net Loss Widening Nine months net loss widened to $(6.08M) compared to $(3.23M) loss last year due to higher operating expenses.
Customer Concentration Exposure High customer concentration risk exists; AnovoRx accounted for 85.8% of net product revenues for the nine months.
ESPP Issuance Halted ESPP share issuance suspended for nine months 2025 due to failure filing required INCRELEX® financial statements.
Substantial Long-Term Debt Long-term debt stands at $27.59M, requiring quarterly principal payments starting May 2026, impacting future cash flow.

見通し

Advancing Late-Stage Pipeline Five late-stage candidates including ET-600 and Amglidia® are advancing development efforts to expand rare disease portfolio.
Liquidity Runway Confirmed Current cash plus product revenues expected sufficient to fund operations for at least the next twelve months period.
Increased R&D Investment R&D spending rose due to $2.16M NDA filing fee for ET-600 and increased ET-700/ET-800 project costs.
Evaluating Tax Disclosure Changes Evaluating impact of new FASB ASU 2023-09 regarding income tax disclosures, effective for annual periods beginning 2025.

同業比較

売上高 (TTM)

Rigel Pharmaceuticals, Inc.RIGL
$282.08M
+79.1%
ADC Therapeutics SAADCT
$75.21M
+6.4%
Lexicon Pharmaceuticals, Inc.LXRX
$70.86M
+1255.2%

粗利益率 (最新四半期)

Alumis Inc.ALMS
100.0%
+0.0pp
Ocugen, Inc.OCGN
100.0%
+0.0pp
Bicycle Therapeutics plcBCYC
100.0%
+1705.8pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
ALMS$2.77B-11.3-75.5%7.7%
CRVS$1.56B-102.5-25.8%1.3%
RAPT$954.54M-14.7-61.8%1.6%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
24.5%
高成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年3月17日
|
EPS:$0.12
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $22.46M+117.5%
    |
    EPS: $-0.07-389.3%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $18.93M+108.6%
    |
    EPS: $-0.10-19.9%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月13日|
    売上高: $17.28M+116.9%
    |
    EPS: $-0.06+85.7%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月18日|
    売上高: $39.01M+23.3%
    |
    EPS: $-0.15-311.0%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月12日|
    売上高: $10.32M+46.9%
    |
    EPS: $0.02-207.6%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月8日|
    売上高: $9.07M-24.4%
    |
    EPS: $-0.12-166.7%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月9日|
    売上高: $7.97M+50.2%
    |
    EPS: $-0.03-71.4%
    予想を上回る

  • Form 10-K/A - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月22日|
    売上高: $31.64M+48.9%
    |
    EPS: $-0.04+89.9%
    予想を上回る